转移灶中PD-L1表达的异质性影响免疫治疗反应。 - Suppr | 超能文献

文献检索
文档翻译
深度研究
学术资讯

Zotero 插件

邀请有礼
套餐&价格
历史记录

应用&插件

Zotero 插件浏览器插件 Mac 客户端 Windows 客户端微信小程序

定价

高级版会员购买积分包购买API积分包

服务

文献检索文档翻译深度研究 API 文档 MCP 服务

关于我们

关于 Suppr 公司介绍联系我们用户协议隐私条款

关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Heterogeneous PD-L1 expression in metastases impacts immunotherapy response.转移灶中PD-L1表达的异质性影响免疫治疗反应。

EBioMedicine. 2023 Nov;97:104816. doi: 10.1016/j.ebiom.2023.104816. Epub 2023 Oct 5.

2

Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.转移性高级别骨肉瘤中 HLA Ⅰ类表达存在时 PD-L1 和 T 细胞浸润增加：基于 T 细胞免疫治疗的理论依据

Cancer Immunol Immunother. 2017 Jan;66(1):119-128. doi: 10.1007/s00262-016-1925-3. Epub 2016 Nov 16.

3

Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.免疫治疗靶向程序性细胞死亡受体 1/程序性细胞死亡配体 1 治疗耐药微卫星稳定结直肠癌伴和不伴肝转移患者的临床反应。

JAMA Netw Open. 2021 Aug 2;4(8):e2118416. doi: 10.1001/jamanetworkopen.2021.18416.

4

Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM.不同组织类型肿瘤 PD-L1 表达与基于 PD-1 的免疫治疗转移性黑色素瘤疗效的相关性——DeCOG 前瞻性多中心队列研究 ADOREG/TRIM 分析。

EBioMedicine. 2023 Oct;96:104774. doi: 10.1016/j.ebiom.2023.104774. Epub 2023 Sep 4.

5

Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.缺乏驱动基因突变的晚期非小细胞肺癌一线PD-1/PD-L1抑制剂的疗效比较：系统评价和贝叶斯网络荟萃分析

Ther Adv Chronic Dis. 2023 Oct 11;14:20406223231189224. doi: 10.1177/20406223231189224. eCollection 2023.

6

Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors.肺转移瘤与相应原发性肿瘤之间肿瘤细胞和免疫细胞上PD-L1表达的差异。

Surg Oncol. 2018 Dec;27(4):637-641. doi: 10.1016/j.suronc.2018.08.001. Epub 2018 Aug 11.

7

Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy.程序性死亡受体配体 1 表达可能独立预测接受免疫治疗的非小细胞肺癌脑转移患者的生存。

Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):258-267. doi: 10.1016/j.ijrobp.2020.04.018. Epub 2020 Apr 23.

8

PD-L1 expression in breast cancer brain metastases.乳腺癌脑转移中程序性死亡受体配体1（PD-L1）的表达

Neurooncol Adv. 2022 Sep 30;4(1):vdac154. doi: 10.1093/noajnl/vdac154. eCollection 2022 Jan-Dec.

9

Radiomics for the non-invasive prediction of PD-L1 expression in patients with brain metastases secondary to non-small cell lung cancer.基于影像组学的非小细胞肺癌脑转移患者 PD-L1 表达的无创预测。

J Neurooncol. 2023 Jul;163(3):597-605. doi: 10.1007/s11060-023-04367-7. Epub 2023 Jun 29.

10

The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study.PD-1/PD-L1抑制剂在非小细胞肺癌肝转移患者中的疗效：一项真实世界研究

Cancers (Basel). 2022 Sep 5;14(17):4333. doi: 10.3390/cancers14174333.

引用本文的文献

1

The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives.新抗原和肿瘤突变负荷在癌症免疫治疗中的作用：进展、机制及展望

J Hematol Oncol. 2025 Sep 2;18(1):84. doi: 10.1186/s13045-025-01732-z.

2

Combining decitabine with radiotherapy to enhance nasopharyngeal carcinoma radiosensitivity via the TFAP2C-OTUD1-SLC25A11 axis.通过TFAP2C-OTUD1-SLC25A11轴将地西他滨与放疗相结合以增强鼻咽癌放射敏感性。

Cell Death Dis. 2025 Jul 15;16(1):525. doi: 10.1038/s41419-025-07858-9.

3

Expression of programmed death receptor-1 ligand (PD-L1) in human cancer is of prognostic value and associated with macrophage infiltration.

程序性死亡受体-1配体（PD-L1）在人类癌症中的表达具有预后价值，并与巨噬细胞浸润相关。

J Cancer. 2024 Nov 4;15(20):6798-6807. doi: 10.7150/jca.99781. eCollection 2024.

4

Evolutionary Trend Analysis of Research on Immunotherapy for Brain Metastasis Based on Machine-Learning Scientometrics.基于机器学习科学计量学的脑转移瘤免疫治疗研究的进化趋势分析

Pharmaceuticals (Basel). 2024 Jun 28;17(7):850. doi: 10.3390/ph17070850.

5

Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities.探索PD-1/PD-L1成像示踪剂领域：从挑战到机遇

Front Med (Lausanne). 2024 Jun 7;11:1401515. doi: 10.3389/fmed.2024.1401515. eCollection 2024.

转移灶中PD-L1表达的异质性影响免疫治疗反应。 - Suppr | 超能文献

Heterogeneous PD-L1 expression in metastases impacts immunotherapy response.

作者信息

Hu Xiaoqian, Deng Xinpei, Xie Jindong, Tang Hailin, Zou Yutian

机构信息

Faculty of Medicine, School of Biomedical Sciences, The University of Hong Kong, 21 Sassoon Road, Hong Kong 999077, China.

State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 651 East Dongfeng Road, Guangzhou 510060, China.

出版信息

EBioMedicine. 2023 Nov;97:104816. doi: 10.1016/j.ebiom.2023.104816. Epub 2023 Oct 5.

DOI:10.1016/j.ebiom.2023.104816

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10570695/

Abstract

摘要